New eye scanner could spot hidden signs of blindness
NCT ID NCT07298174
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will test a new, non-invasive eye scanner called wide field OCTA in 200 people with various eye diseases, including age-related macular degeneration, diabetic retinopathy, and dry eye. The goal is to see if this device can provide better images of blood vessels in the back and front of the eye than current standard tools. Researchers hope it will help doctors diagnose and track eye diseases more accurately.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Wide field OCTA imaging device
- What this could lead to
- If successful, this could lead to better, non-invasive diagnosis and monitoring of eye diseases like macular degeneration and diabetic retinopathy.
- What could go wrong
- This is an early observational study, not a treatment trial. The device may not prove more useful than existing methods, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients affected by ocular diseases and healthy controls to be considered as reference.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age \> 18 years * Both genders * Confirmed diagnosis of one of the above diseases * Age-related macular degeneration * Diabetic retinopathy * Myopia * Pachychoroid spectrum disease * Inherited retinal dystrophy * Uveitis * Dry eye * Visual acuity of at least 1/20 * Signed informed consent for the participation to the trial. Exclusion Criteria: * Media opacities * Any other eye or systemic condition that may irreversibly impair the results of the study * Surgery in the eye in the study, including cataract extraction, in the three months prior to recruitment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Age-related macular degeneration (AMD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Modified vitamin a pill tested against inherited blindness
- Two lens designs go Head-to-Head for aging eyes
- Vitamin a derivative eyed to halt inherited blindness
- Could a work health check catch diabetic eye damage before it steals sight?
- Can AI protect Kids' eyesight where eye doctors are scarce?
- Two toric lenses go head to head in vision test